Please assess the completion status of the following clinical trial:

Trial Title: Safety, Pharmacokinetics and Efficacy of Bimagrumab in Overweight and Obese Patients With Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Type 2 diabetes with HbA1c between 6.5% and 10% at screening with stable treatment for 3 months prior to randomization~* On one of the following anti-diabetes regimens with stable treatment for approximately 3 months prior to randomization: 1) metformin monotherapy; 2) DPP4 inhibitor agent monotherapy; 3) combination therapy of metformin and DPP4 inhibitor agent; 4) no anti-diabetes therapy.~* Body Mass Index of 28 to 40 kg/m2 at screening~* Body weight between 65 and 140 kg at screening~Exclusion Criteria:~* Women of child-bearing potential unless they are using highly effective methods of contraception~* Diabetes other than Type 2 such as Type 1 diabetes, surgically induced diabetes, brittle type 2 diabetes as per investigator judgement, history of severe hypoglycemic episodes in the year preceding screening or hypoglycemic unawareness~* History of clinically significant arrythmias, heart failure, unstable angina, myocardial infarction or stroke, coronary artery bypass graft surgery, or percutaneous coronary intervention, deep vein thrombosis/pulmonary embolism, valve disorders or defects, pulmonary hypertension within 6 months of screening or 1 year for drug-eluting stents~* Tachycardia~* Use of anti-obesity medications, nutritional supplements or over the counter products for weight loss within 3 months of screening~* Use of medications known to induce weight gain such as some anti-convulsant and psychotropic medications within 3 months of screening~* Any chronic active infection (e.g., HIV, Hepatitis B or C, tuberculosis, etc) or has received anti-HCV treatments within the previous 6 months.~* Uncontrolled thyroid disease. Stable euthyroid patients on stable thyroid replacement therapy for at least 3 months of screening are allowed.~* Abnormal liver function tests such as SGOT, SGPT, alkaline phosphatase, or serum bilirubin, or abnormal lipase and/or amylase.~* Known history or presence of severe active acute or chronic liver disease (e.g., cirrhosis).~* Uncontrolled depression~* Use of skeletal muscle anabolic agents in any form for 3 months prior to screening~* Chronic kidney disease \[estimated glomerular filtration rate (GFR) \< 30 mL/min\];

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- BYM338 10 mg/kg (Type: EXPERIMENTAL): Bimagrumab (BYM338) 10 mg/kg up to maximum 1200 mg, every 4 weeks until week 44 (12 doses)
- Placebo (Type: PLACEBO_COMPARATOR): Placebo, every 4 weeks until week 44 (12 doses)

Based on this trial design, predict the completion outcome and termination type (if applicable).